164 related articles for article (PubMed ID: 1420749)
41. An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry.
Zentilin P; Dulbecco P; Savarino E; Parodi A; Iiritano E; Bilardi C; Reglioni S; Vigneri S; Savarino V
Aliment Pharmacol Ther; 2005 Jan; 21(1):29-34. PubMed ID: 15644042
[TBL] [Abstract][Full Text] [Related]
42. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.
Mandel KG; Daggy BP; Brodie DA; Jacoby HI
Aliment Pharmacol Ther; 2000 Jun; 14(6):669-90. PubMed ID: 10848650
[TBL] [Abstract][Full Text] [Related]
43. Effects of Algicon on the ultrastructure of the mucosa of subjects with reflux oesophagitis.
Trabucchi E; Foschi D; Radaelli E; Callioni F; Montorsi W
Br J Clin Pract Suppl; 1989 Feb; 66():43-7; discussion 61-4. PubMed ID: 2511922
[No Abstract] [Full Text] [Related]
44. Effect of alginate in patients with GERD hiatal hernia matters.
Vardar R; Keskin M; Valitova E; Bayrakci B; Yildirim E; Bor S
Dis Esophagus; 2017 Oct; 30(10):1-7. PubMed ID: 28859383
[TBL] [Abstract][Full Text] [Related]
45. Comparison of a dimethicone/antacid (Asilone gel) with an alginate/antacid (Gaviscon liquid) in the management of reflux oesophagitis.
Smart HL; Atkinson M
J R Soc Med; 1990 Sep; 83(9):554-6. PubMed ID: 2213800
[TBL] [Abstract][Full Text] [Related]
46. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
[TBL] [Abstract][Full Text] [Related]
47. Combined cimetidine-alginate antacid therapy versus single agent treatment for reflux oesophagitis: results of prospective double-blind randomised clinical trial.
Eriksen CA; Cheadle WG; Cranford CA; Cuschieri A
Ann Chir Gynaecol; 1988; 77(4):133-7. PubMed ID: 2855391
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and tolerance of Algicon in patients with reflux oesophagitis.
Lancaster Smith MJ; Miller JP; Whorwell PJ
Br J Clin Pract Suppl; 1989 Feb; 66():38-42; discussion 61-4. PubMed ID: 2511921
[No Abstract] [Full Text] [Related]
49. Comparison of Algicon and ranitidine in the therapy of reflux oesophagitis: preliminary results.
Pace F; Sangaletti O; Bianchi Porro G
Br J Clin Pract Suppl; 1989 Feb; 66():59-60; discussion 61-4. PubMed ID: 2511924
[No Abstract] [Full Text] [Related]
50. A study of Algicon, an antacid-alginate preparation, in patients with reflux oesophagitis.
Maxton DG; Miller JP; Whorwell PJ; Butler JK
Br J Clin Pract; 1988 Sep; 42(9):368-71. PubMed ID: 3075928
[No Abstract] [Full Text] [Related]
51. Effect of time of dosing relative to a meal on the raft formation of an anti-reflux agent.
Washington N; Greaves JL; Wilson CG
J Pharm Pharmacol; 1990 Jan; 42(1):50-3. PubMed ID: 1969950
[TBL] [Abstract][Full Text] [Related]
52. [Influence of sodium alginate on the intestinal transit in low birth weight newborn infants].
Chouraqui JP; Morer I; Renard P; Bielsky MC; Richard-Berthe C; Rambaud P
Pediatrie; 1993; 48(6):473-7. PubMed ID: 8247649
[TBL] [Abstract][Full Text] [Related]
53. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor.
Reimer C; Lødrup AB; Smith G; Wilkinson J; Bytzer P
Aliment Pharmacol Ther; 2016 Apr; 43(8):899-909. PubMed ID: 26909885
[TBL] [Abstract][Full Text] [Related]
54. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients.
Kwiatek MA; Roman S; Fareeduddin A; Pandolfino JE; Kahrilas PJ
Aliment Pharmacol Ther; 2011 Jul; 34(1):59-66. PubMed ID: 21535446
[TBL] [Abstract][Full Text] [Related]
55. [Gaviscon].
Ménégol-Couque B; Brard M
Soins; 1985 Jun; (455):I-II. PubMed ID: 2994235
[No Abstract] [Full Text] [Related]
56. [Using gaviscon preparation for relief of esophageal, extraesophageal syndromes and functional dyspepsia in elderly patients with GERD].
Onuchina EV; Brikova SI; Tsukanov VV
Eksp Klin Gastroenterol; 2010; (10):80-6. PubMed ID: 21434379
[TBL] [Abstract][Full Text] [Related]
57. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.
Wilkinson J; Wade A; Thomas SJ; Jenner B; Hodgkinson V; Coyle C
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):86-93. PubMed ID: 30272584
[TBL] [Abstract][Full Text] [Related]
58. Gaviscon and domperidon responsive apnea episodes associated with gastro-esophageal reflux disease in twins.
Bilgin H; Eren A; Kara S
Asia Pac J Clin Nutr; 2015; 24(4):753-5. PubMed ID: 26693761
[TBL] [Abstract][Full Text] [Related]
59. Managing childhood gastro-oesophageal reflux.
Drug Ther Bull; 1997 Oct; 35(10):77-80. PubMed ID: 9489057
[No Abstract] [Full Text] [Related]
60. [Restoration of the quality of life by eliminating and prevention of heartburn by alginate: results of multicenter study "VIA APIA"].
Lazebnik LB; Bordin DS; Masharova AA; Dzhulaĭ GS; Butov MA; Abdulkhakov RA; Eremina EIu; Tarasova LV; Safonova OV; Firsova LD; Kozhurina TS
Eksp Klin Gastroenterol; 2010; (6):70-6. PubMed ID: 20731169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
